Wall Street brokerages expect Ra Pharmaceuticals Inc (NASDAQ:RARX) to report ($0.74) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Ra Pharmaceuticals’ earnings. Ra Pharmaceuticals reported earnings per share of ($14.22) during the same quarter last year, which would indicate a positive year over year growth rate of 94.8%. The company is scheduled to report its next quarterly earnings report on Tuesday, December 5th.

According to Zacks, analysts expect that Ra Pharmaceuticals will report full year earnings of ($2.55) per share for the current financial year, with EPS estimates ranging from ($2.63) to ($2.46). For the next year, analysts anticipate that the business will report earnings of ($3.15) per share, with EPS estimates ranging from ($3.55) to ($2.75). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Ra Pharmaceuticals.

Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.06).

A number of research firms have recently weighed in on RARX. Zacks Investment Research upgraded Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 5th. Royal Bank Of Canada began coverage on Ra Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $21.00 target price for the company. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $25.00 target price on shares of Ra Pharmaceuticals in a research report on Friday, July 14th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.00.

Several institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its holdings in shares of Ra Pharmaceuticals by 30.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after buying an additional 2,543 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of Ra Pharmaceuticals by 97.0% during the 1st quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after buying an additional 3,859 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Ra Pharmaceuticals by 26.1% during the 2nd quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after buying an additional 4,300 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Ra Pharmaceuticals by 7.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock worth $1,370,000 after buying an additional 4,751 shares in the last quarter. Finally, American International Group Inc. acquired a new position in shares of Ra Pharmaceuticals during the 1st quarter worth $102,000. 66.26% of the stock is owned by institutional investors.

Ra Pharmaceuticals (NASDAQ RARX) remained flat at $14.60 on Friday. The company’s stock had a trading volume of 107,249 shares. Ra Pharmaceuticals has a 1-year low of $12.05 and a 1-year high of $24.12. The company’s market cap is $330.09 million. The firm has a 50 day moving average price of $14.70 and a 200-day moving average price of $14.70.

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/0-74-earnings-per-share-expected-for-ra-pharmaceuticals-inc-rarx-this-quarter/1599558.html.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.